Lupin Limited has received recommendations from the Subject Expert Committee (SEC) under the Central Drugs Standard Control ...

Indias top drugmakers, Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN), are moving closer to developing ...

Mumbai: Lupin has announced that the U.S. Food and Drugs Administration (USFDA) has closed the inspection with six ...

Lupin shares declined nearly 2% on Wednesday on news that the US Food and Drug Administration (USFDA) issued six observations ...

Lupin has received USFDA approval to market generic Lenalidomide capsules, a version of Bristol-Myers Squibb's cancer drug Revlimid, which posted $7.5 bn US sales in July 2025 ...

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma, in combination with ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in ...

USFDA inspections at Lupin, Zydus, and Aurobindo facilities result in observations, commitment to compliance with quality ...

In its base case, Investec expects a strong FY26, followed by moderation in FY27, with EPS growth resuming in FY28. In the ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced ...

Lupin has been granted approval by the USFDA to market Lenalidomide Capsules, a cancer treatment drug, in the US. The drug, a bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at ...

Indian pharma stocks lag Nifty in 2025 as US demand, pricing pressure and FDA scrutiny weigh; domestic growth offers some ...